Canada Markets closed

Sensei Biotherapeutics, Inc. (SNSE)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
4.8000-0.3100 (-6.07%)
At close: 04:00PM EST
4.8000 0.00 (0.00%)
After hours: 04:31PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close5.1100
Open5.0500
Bid4.5200 x 3100
Ask7.8100 x 3200
Day's Range4.8000 - 5.1300
52 Week Range4.7000 - 26.5000
Volume78,027
Avg. Volume86,520
Market Cap146.865M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.5870
Earnings DateMar. 23, 2022 - Mar. 28, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.00
  • Simply Wall St.

    Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) insiders placed bullish bets worth US$1.0m in the last 12 months

    When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase...

  • GlobeNewswire

    Sensei Biotherapeutics Announces Executive Promotions

    Company names Erin Colgan as chief financial officer and Robert Pierce, M.D. as chief R&D officerBOSTON, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced two key promotions within the company’s senior management team. Erin Colgan, formerly senior vice president of finance and administration, has been appointed to chief financial officer. Robe

  • GlobeNewswire

    Sensei Biotherapeutics Named a Winner of Comparably’s Best CEO Award

    BOSTON, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced that it has won a Comparably award for 2021 “Best CEOs.” “What makes Comparably awards so meaningful is that they are based exclusively on employee feedback,” said Elisabeth Colunio, Vice President of Human Resources. “We are thrilled but not surprised to see John recognized as a 2021 B